The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review

Main Article Content

Michael Roche (1*), Laura Parisi (2), Linda Li (3), Amy Knehans (4), Rebecca Phaeton (5), Joshua P. Kesterson (6)

1 Department of Obstetrics and Gynecology, Penn State Hershey Medical Center, Hershey, Pennsylvania, United States.
2 Department of Obstetrics and Gynecology, The University of Kansas Medical Center, Kansas City, Kansas, United States.
3 Department of Obstetrics and Gynecology, Penn State Hershey Medical Center, Hershey, Pennsylvania, United States.
4 Harrell Health Sciences Library, Penn State College of Medicine, Hershey, Pennsylvania, United States.
5 Division of Gynecologic Oncology, Penn State Hershey Medical Center, Hershey, Pennsylvania, United States.
6 Division of Gynecologic Oncology, Penn State Hershey Medical Center, Hershey, Pennsylvania, United States.
(*) Corresponding Author:
Michael Roche
mroche@pennstatehealth.psu.edu
http://orcid.org/0000-0003-4186-1969

Abstract

Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (AlimtaTM) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current literature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

How to Cite
Roche, M., Parisi, L., Li, L., Knehans, A., Phaeton, R., & Kesterson, J. P. (2018). The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review. Oncology Reviews, 12(1). https://doi.org/10.4081/oncol.2018.346